{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T03:13:25Z","timestamp":1794453205595,"version":"4.9.1"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T00:00:00Z","timestamp":1611878400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007819","name":"Allergan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019851","name":"Aldeyra Therapeutics","doi-asserted-by":"publisher","award":["163:461\u2013464"],"award-info":[{"award-number":["163:461\u2013464"]}],"id":[{"id":"10.13039\/100019851","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007489","name":"Bausch and Lomb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007489","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.ajo.2021.01.011","type":"journal-article","created":{"date-parts":[[2021,1,30]],"date-time":"2021-01-30T07:55:29Z","timestamp":1611993329000},"page":"22-31","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"special_numbering":"C","title":["Early Onset and Broad Activity of Reproxalap in a Randomized, Double-Masked, Vehicle-Controlled Phase 2b Trial in Dry Eye Disease"],"prefix":"10.1016","volume":"226","author":[{"given":"David","family":"Clark","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5365-8795","authenticated-orcid":false,"given":"Joseph","family":"Tauber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Sheppard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3399-4673","authenticated-orcid":false,"given":"Todd C.","family":"Brady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajo.2021.01.011_bib0001","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ajo.2017.06.033","article-title":"Prevalence of diagnosed dry eye disease in the United States among adults aged 18 years and older","volume":"182","author":"Farrand","year":"2017","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"10.1016\/j.ajo.2021.01.011_bib0002","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jtos.2017.05.003","article-title":"TFOS DEWS II epidemiology report","volume":"15","author":"Stapleton","year":"2017","journal-title":"Ocul Surf"},{"key":"10.1016\/j.ajo.2021.01.011_bib0003","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2147\/OPTH.S126668","article-title":"Dry eye syndrome: developments and lifitegrast in perspective","volume":"12","author":"Lollett","year":"2018","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.ajo.2021.01.011_bib0004","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.2147\/OPTH.S226168","article-title":"Real-world treatment patterns of cyclosporine ophthalmic emulsion and lifitegrast ophthalmic solution among patients with dry eye","volume":"13","author":"White","year":"2019","journal-title":"Clin Ophthalmol"},{"issue":"6","key":"10.1016\/j.ajo.2021.01.011_bib0005","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.ajo.2011.11.003","article-title":"A phase 2 randomized, double-masked, placebo-controlled study of a novel integrin antagonist (SAR 1118) for the treatment of dry eye","volume":"153","author":"Semba","year":"2012","journal-title":"Am J Ophthalmol"},{"issue":"12","key":"10.1016\/j.ajo.2021.01.011_bib0006","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1016\/j.ophtha.2015.08.001","article-title":"Lifitegrast ophthalmic solution 5.0% versus placebo for treatment of dry eye disease: results of the randomized phase III OPUS-2 Study","volume":"122","author":"Tauber","year":"2015","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.ajo.2021.01.011_bib0007","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1042\/BJ20111752","article-title":"Cell signalling by reactive lipid species: new concepts and molecular mechanisms","volume":"442","author":"Higdon","year":"2012","journal-title":"Biochem J"},{"issue":"1","key":"10.1016\/j.ajo.2021.01.011_bib0008","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.exer.2007.09.010","article-title":"Carotenoid derived aldehydes-induced oxidative stress causes apoptotic cell death in human retinal pigment epithelial cells","volume":"86","author":"Kalariya","year":"2008","journal-title":"Exp Eye Res"},{"issue":"1-2","key":"10.1016\/j.ajo.2021.01.011_bib0009","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.imlet.2012.05.005","article-title":"Oxidative stress activates NLRP3 inflammasomes in ARPE-19 cells\u2014implications for age-related macular degeneration (AMD)","volume":"147","author":"Kauppinen","year":"2012","journal-title":"Immunol Lett"},{"issue":"1","key":"10.1016\/j.ajo.2021.01.011_bib0010","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12931-017-0517-x","article-title":"Malondialdehyde-acetaldehyde (MAA) adducted surfactant protein induced lung inflammation is mediated through scavenger receptor a (SR-A1)","volume":"18","author":"Sapkota","year":"2017","journal-title":"Respir Res"},{"issue":"5","key":"10.1016\/j.ajo.2021.01.011_bib0011","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1080\/00015550310003782","article-title":"Lipid peroxidation and antioxidant defence system in patients with active or inactive Beh\u00e7et's disease","volume":"83","author":"Sandikci","year":"2003","journal-title":"Acta Derm Venereol"},{"issue":"9","key":"10.1016\/j.ajo.2021.01.011_bib0012","first-page":"997","article-title":"The role of conjunctival epithelial cell xanthine oxidoreductase\/xanthine oxidase in oxidative reactions on the ocular surface of dry eye patients with Sjogren's syndrome","volume":"22","author":"Cejkova","year":"2007","journal-title":"Histol Histopathol"},{"key":"10.1016\/j.ajo.2021.01.011_bib0013","first-page":"443","article-title":"Investigation of oxidative stress in pterygium tissue","volume":"17","author":"Balci","year":"2011","journal-title":"Mol Vis"},{"issue":"2","key":"10.1016\/j.ajo.2021.01.011_bib0014","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3109\/09273948.2013.830753","article-title":"Serum anti-carbonic anhydrase antibodies and oxidant-antioxidant balance in patients with acute anterior uveitis","volume":"22","author":"Turk","year":"2014","journal-title":"Ocul Immunol Inflamm"},{"issue":"3","key":"10.1016\/j.ajo.2021.01.011_bib0015","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00441-004-1030-3","article-title":"Anti-oxidative vitamins prevent lipid-peroxidation and apoptosis in corneal endothelial cells","volume":"320","author":"Serbecic","year":"2005","journal-title":"Cell Tissue Res"},{"issue":"1","key":"10.1016\/j.ajo.2021.01.011_bib0016","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1159\/000081783","article-title":"The protective effect of alpha-lipoic acid against oxidative damage in rabbit conjunctiva and cornea exposed to ultraviolet radiation","volume":"219","author":"Demir","year":"2005","journal-title":"Ophthalmologica"},{"issue":"8","key":"10.1016\/j.ajo.2021.01.011_bib0017","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1136\/bjo.2009.161679","article-title":"Oxidative stress of intracameral lidocaine and levobupivacaine on ocular tissues","volume":"94","author":"Demir","year":"2010","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2021.01.011_bib0018","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.jaci.2005.06.002","article-title":"Effect of pollen-mediated oxidative stress on immediate hypersensitivity reactions and late-phase inflammation in allergic conjunctivitis","volume":"116","author":"Bacsi","year":"2005","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.ajo.2021.01.011_bib0019","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1006\/bcmd.1999.0234","article-title":"Antioxidant enzymatic activities in human blood cells after an allergic reaction to pollen or house dust mite","volume":"25","author":"Mates","year":"1999","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.ajo.2021.01.011_bib0020","first-page":"2465","article-title":"Evaluation of lipid oxidative stress status and inflammation in atopic ocular surface disease","volume":"16","author":"Wakamatsu","year":"2010","journal-title":"Mol Vis"},{"issue":"11","key":"10.1016\/j.ajo.2021.01.011_bib0021","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1007\/BF00164671","article-title":"Oxidative reactions in the tear fluid of patients suffering from dry eyes","volume":"233","author":"Augustin","year":"1995","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"9","key":"10.1016\/j.ajo.2021.01.011_bib0022","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.3109\/02713683.2015.1098707","article-title":"Expression of lipid peroxidation markers in the tear film and ocular surface of patients with non-Sjogren syndrome: potential biomarkers for dry eye disease","volume":"41","author":"Choi","year":"2016","journal-title":"Curr Eye Res"},{"issue":"10","key":"10.1016\/j.ajo.2021.01.011_bib0023","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1089\/jop.2020.0056","article-title":"Randomized phase 2 trial of reproxalap, a novel reactive aldehyde species inhibitor, in patients with noninfectious anterior uveitis: model for corticosteroid replacement","volume":"36","author":"Mandell","year":"2020","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.ajo.2021.01.011_bib0024","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.2147\/OPTH.S44688","article-title":"Safety and efficacy of MIM-D3 ophthalmic solutions in a randomized, placebo-controlled Phase 2 clinical trial in patients with dry eye","volume":"7","author":"Meerovitch","year":"2013","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.ajo.2021.01.011_bib0025","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2147\/OPTH.S38732","article-title":"Exacerbation of signs and symptoms of allergic conjunctivitis by a controlled adverse environment challenge in subjects with a history of dry eye and ocular allergy","volume":"7","author":"Gomes","year":"2013","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.ajo.2021.01.011_bib0026","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2147\/OPTH.S39356","article-title":"Investigation of extended blinks and interblink intervals in subjects with and without dry eye","volume":"7","author":"Rodriguez","year":"2013","journal-title":"Clin Ophthalmol"},{"issue":"5","key":"10.1016\/j.ajo.2021.01.011_bib0027","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1001\/archopht.118.5.615","article-title":"Reliability and validity of the Ocular Surface Disease Index","volume":"118","author":"Schiffman","year":"2000","journal-title":"Arch Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajo.2021.01.011_bib0028","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S1542-0124(12)70053-8","article-title":"Development and validation of a short global dry eye symptom index","volume":"5","author":"Schaumberg","year":"2007","journal-title":"Ocul Surf"},{"issue":"5","key":"10.1016\/j.ajo.2021.01.011_bib0029","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/01.MLR.0000062554.74615.4C","article-title":"Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation","volume":"41","author":"Norman","year":"2003","journal-title":"Med Care"},{"issue":"suppl 11","key":"10.1016\/j.ajo.2021.01.011_bib0030","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.ophtha.2017.07.010","article-title":"The pathophysiology of dry eye disease: what we know and future directions for research","volume":"124","author":"Pflugfelder","year":"2017","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1016\/j.ajo.2021.01.011_bib0031","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1097\/01.ico.0000157421.93522.00","article-title":"Distribution of conjunctival HLA-DR expression and the pathogenesis of damage in early dry eyes","volume":"24","author":"Rolando","year":"2005","journal-title":"Cornea"},{"issue":"2","key":"10.1016\/j.ajo.2021.01.011_bib0032","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ajo.2008.08.032","article-title":"Tear cytokine profiles in dysfunctional tear syndrome","volume":"147","author":"Lam","year":"2009","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"10.1016\/j.ajo.2021.01.011_bib0033","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jtos.2017.05.011","article-title":"TFOS DEWS II pathophysiology report","volume":"15","author":"Bron","year":"2017","journal-title":"Ocul Surf"},{"issue":"3","key":"10.1016\/j.ajo.2021.01.011_bib0034","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1136\/bjophthalmol-2015-307415","article-title":"Revisiting the vicious circle of dry eye disease: a focus on the pathophysiology of meibomian gland dysfunction","volume":"100","author":"Baudouin","year":"2016","journal-title":"Br J Ophthalmol"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939421000313?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939421000313?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T13:44:49Z","timestamp":1757598289000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939421000313"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":34,"alternative-id":["S0002939421000313"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2021.01.011","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Early Onset and Broad Activity of Reproxalap in a Randomized, Double-Masked, Vehicle-Controlled Phase 2b Trial in Dry Eye Disease","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2021.01.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}